Tools for Practice Outils pour la pratique


#42 Children with Acute Otitis Media: Benefits and Risks of Antibiotics


CLINICAL QUESTION
QUESTION CLINIQUE
 In children with acute otitis media (AOM) what are benefits and risks of antibiotics?

BOTTOM LINE
RÉSULTAT FINAL
 Although most children will recover from acute otitis media without complications, antibiotics will improve outcomes for 1 in 3 to 1 in 10, depending on outcome and complicating factors. Antibiotics will cause adverse events, particularly diarrhea, in up to 1 in every 5.


CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

 Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session


EVIDENCE
DONNÉES PROBANTES
 Randomized Controlled Trial (RCT):1 319 patients, age 6-35 months. 
  • Amoxicillin/clavulanate (40/5.7 mg/kg/day) versus placebo, divided BID x7 days 
    • Treatment failure day eight: 19% (antibiotic) versus 45% (placebo), Number Needed to Treat (NNT)=4. 
    • Reduced absenteeism for child (day-care) and parent (work), more fever resolution, less contra-lateral AOM, fewer rescue treatments, etc. 
  • Antibiotics increased adverse events: Eczema Number Needed to Harm (NNH)=19, any diarrhea NNH=5 and for “a lot” of diarrhea NNH=12. 
RCT:2 291 patients, age 6-23 months. 
  • Amoxicillin/clavulanate (90/6.4 mg/kg/day) versus placebo, divided BID x10 days. 
    • Clinical failure day 4-5: 4% versus 23%, NNT=6. 
    • Day 10-12: 16% versus 51%, NNT=3. 
  • Antibiotics increased adverse events: Diarrhea NNH=10, diaper rash NNH=7. 
RCT:3 84 patients, 85% ≤5 years old. 
  • Amoxicillin/clavulanate (40 mg/kg/day) versus placebo, divided BID x7 days. 
    • Resolution of middle ear effusion: 18.9 versus 32.6 days.   
    • Ear ache five days after initiation: 0% versus 17%, NNT=6. 
  • Three systematic reviews:4-6 7-15 RCTs (2,079-4,500 patients), antibiotic versus placebo, similar results. 
    • Persistent pain:6 At 24 hours no difference; At 2-3 days NNT=24; At 4-7 days NNT=17. 
    • Treatment success at 14 days:4 NNT=9. 
    • Less perforation and contralateral infection.6 
    • Vomiting, diarrhea, or rash:6 NNH=14. 
Context:  
  • Natural history: 70% of untreated children have resolution at 7-14 days.1,2,4 
  • Poor Prognostic Indicators: Bilateral Otitis Media,2,7 age <24 months,7 exposure to more children (day-care),2 and more severe symptom scores.2 
  • Types of antibiotics: No reliable difference in the efficacy of antibiotics studied.4   
    • Amoxicillin is the most commonly studied and recommended.4,8    
  • Delayed versus immediate prescriptions:  
    • Four studies, two found no difference and two found immediate prescriptions superior (NNT=6-7).4  
    • Delayed prescriptions may increase patient dissatisfaction.9 
updated mar 10 2015 by braiden

Latest Tools for Practice
Derniers outils pour la pratique
program image
Allison Paige MD CCFP

#364 Facing the Evidence in Acne, Part II: Oral Antibiotics

How effective are oral antibiotics in treating acne of at least mild-moderate severity?
Read Lire 0.25 credits available Crédits disponibles
program image
Bradley LeDrew PharmD candidate

#363 Making a difference in indifference? Medications for apathy in dementia

In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
Read Lire 0.25 credits available Crédits disponibles
program image
Allison Paige MD CCFP

#362 Facing the Evidence in Acne, Part I: Oral contraceptives and spironolactone in females

How effective are combined oral contraceptives (COC) and spironolactone for treating acne of at least mild-moderate severity in females?
Read Lire 0.25 credits available Crédits disponibles
February 22, 2011

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session
Author(s)
Auteur(s)
  • Christina Korownyk MD CCFP
  • G. Michael Allan MD CCFP

1. Tähtinen PA, Laine MK, Huovinen P, et al. N Engl J Med. 2011; 364:116-26.

2. Hoberman A, Paradise JL, Rockette HE, et al. N Engl J Med. 2011; 364:105-15.

3. Tapiainen T, Kujala T, Renko M, et al. JAMA Pediatr. 2014; 168(7):635-41.

4. Coker TR, Chan LS, Newberry SJ, et al. JAMA. 2010; 304(19):2161-9.

5. Gisselsson-Solen M. Int J Pediatr Otorhinolaryngol. 2014; 78(8):1221-7.

6. Venekamp RP, Sanders S, Glasziou PP, et al. Cochrane Database Syst Rev. 2013; 1:CD000219.

7. Rovers MM, Glasziou P, Appelman CL, et al. Pediatrics. 2007; 119;579-85.

8. S Forgie, G Zhanel, J Robinson. Paediatr Child Health. 2009; 14(7):457-60.

9. Spurling GK, Del Mar CB, Dooley L, et al. Cochrane Database Syst Rev. 2013; 4:CD004417.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.